• Nenhum resultado encontrado

[PDF] Top 20 Chemotherapy and Targeted therapy in Hormone Refractory Prostate Cancer (HRPC)

Has 10000 "Chemotherapy and Targeted therapy in Hormone Refractory Prostate Cancer (HRPC)" found on our website. Below are the top 20 most common "Chemotherapy and Targeted therapy in Hormone Refractory Prostate Cancer (HRPC)".

Chemotherapy and Targeted therapy in Hormone Refractory Prostate Cancer (HRPC)

Chemotherapy and Targeted therapy in Hormone Refractory Prostate Cancer (HRPC)

... HRPC is often associated with the development of painful bone meta- stases. Newer generation bisphos- phonates may relieve pain caused by bone metastases, prevent treatment- related loss of bone mineral density, possibly ... See full document

5

Int. braz j urol.  vol.30 número4

Int. braz j urol. vol.30 número4

... metastases and presented as their only abnormality a slow increase in serum PSA, forming, thus, a selected population that is different from the 2 studies previously ...mentioned. In our Department ... See full document

7

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

... found in the PAC120 tumor but appeared in 28% (10/36) of AI variant ...shown in the Figure S3. Mutations occurred in 46%, 17%, and 25% after complete blockade, antiandrogens and ... See full document

10

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

... National Cancer Institute (NCI) has embarked on the Exceptional Responders Initia- tive (ERI) to understand the molecular underpinnings of exceptional responses to treatment ...mutations in a lung ... See full document

12

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.

... Chemo- therapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Sys- tematic Review and Meta-Analysis of the ... See full document

2

Einstein (São Paulo)  vol.15 número3

Einstein (São Paulo) vol.15 número3

... long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled ... See full document

6

Int. braz j urol.  vol.36 número3

Int. braz j urol. vol.36 número3

... better in terms of progression-free survival and in terms of overall survival compared to castration if non-steroidal rather than steroidal ARBs are used (3- 6), but at the cost of greater ...line ... See full document

8

Prostate Cancer Exosomes As Molecular Predictors Of Response To Therapy

Prostate Cancer Exosomes As Molecular Predictors Of Response To Therapy

... developed and carefully evaluated in clinical trials, with the most commonly used AR-axis-targeted (ARAT) therapies for the treatment of mCRPC being Abiraterone Acetate (AA) and Enzalutamide ... See full document

57

Esc. Anna Nery  vol.18 número4

Esc. Anna Nery vol.18 número4

... for prostate cancer, this study speciically addresses hormone therapy because this is a therapeutic option that is possible in any of the disease ...irst-line hormone treatment ... See full document

5

Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy

Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy

... used in small interfering RNA (siRNA) delivery for prostate cancer ...siRNA. In an exploratory study of siRNA delivery, the A10 aptamer was directly linked to an siRNA to form the ... See full document

8

Cancer stem cells in prostate cancer: implications for targeted therapy

Cancer stem cells in prostate cancer: implications for targeted therapy

... Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the second most common cause of cancer-related mortality among men in the developed ...advanced ... See full document

12

Einstein (São Paulo)  vol.8 número3

Einstein (São Paulo) vol.8 número3

... patients in this pilot study is small, three patients out of 12 clearly derived significant benefit from ...on hormone-refractory ...MX+E and achieved a partial response lasting four ... See full document

3

Stem and progenitor cell-mediated tumor selective gene therapy

Stem and progenitor cell-mediated tumor selective gene therapy

... metastatic and invasive tumors and the toxic side effects of currently available treatments necessitate the development of effective tumor-selective ...effective targeted therapy for these ... See full document

14

Active targeted therapy to cancer diseases mediated by lectins

Active targeted therapy to cancer diseases mediated by lectins

... glycoconjugate in a reversible, noncovalent and highly specific manner (Van Damme et ...specificity and reversible carbohydrate binding combined with vast anticancer potential due to their ability to ... See full document

44

Figure 2 (A) High definition axial T1-weighted MRI post-Gd clearly depicts rectal tumor, with transmural stranding in mesorectal

Figure 2 (A) High definition axial T1-weighted MRI post-Gd clearly depicts rectal tumor, with transmural stranding in mesorectal

... located in the ...namely in terms of local ...both in staging procedures as well as in neoadjuvant and adjuvant chemoradiation ...rectal cancer staging. Also, pre- operative ... See full document

9

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

... months and those remaining alive assuming a perfect declining exponential ...difference in their median survival between their individual subgroups with and without baseline pain ...method, ... See full document

11

Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer.

Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer.

... DU145 and stably transfected DU145-PTHrP(1- 173)-GFP cells were freshly trypsinized, counted, and placed on ice immediately before ...animal in a total volume of ...tumors and implanted into ... See full document

8

Recent Advances and Perspectives in Cancer Drug Design

Recent Advances and Perspectives in Cancer Drug Design

... between targeted and cytotoxic compounds. ADC therapy aims to reduce the side effects associated with the non-selective nature of cytotoxic drugs (Chari ...(iii) and a drug that needs to be ... See full document

18

Prostate Cancer: A State of The Heart

Prostate Cancer: A State of The Heart

... studies in patients after orchiectomy was presented, which showed that LHRH agonists are associated with a breakthrough of testosterone levels, with 20% of patients unable to consistently drop their levels below ... See full document

6

Platinum complexes in cancer chemotherapy.

Platinum complexes in cancer chemotherapy.

... O DNA é uma macromolécula composta por blocos repeti- tivos, cada um deles constituído de uma base nitrogenada, um grupo fosfato e uma molécula do açúcar 2'-desoxi-D-ribose. As bases nitrogenadas são usualmente as bases ... See full document

9

Show all 10000 documents...